MATTHEWS, N.C. (PRWEB)
March 26, 2020

Harris Teeter today announced it will expand its shopping hours for seniors amid the COVID-19 pandemic. Beginning Monday, March 30, the company will offer two hours for senior shoppers aged 60 and over each Monday and Thursday from 6 a.m. to 8 a.m. until further notice. To further enhance its commitment to protecting its senior shoppers, Harris Teeter will open its Pharmacies at 7 a.m. every Monday and Thursday and provide more fresh offerings during the designated senior shopping hours.

Harris Teeter is also designating ExpressLane Online Shopping pick-up times from 9 a.m. to 2 p.m. for seniors only every Thursday. The company will waive the $4.95 fee and offer $5 delivery (normally $10) for seniors during these times.

“The designated shopping hours will provide a genuine opportunity for senior shoppers to purchase what they need while practicing the CDC’s recommended social distancing guidelines,” said Danna Robinson, communication manager for Harris Teeter. “As the situation continues to evolve, we are listening to our associates and shoppers feedback and will modify our plans to best serve the needs of our communities.”

The company invites its Senior shoppers to take advantage of the 5% Senior Club discount every Thursday.

For the most updated information regarding COVID-19, shoppers are encouraged to visit https://www.harristeeter.com/harris-teeter-response-to-covid-19.

http://www.harristeeter.com

Harris Teeter, with headquarters in Matthews, N.C., is a wholly-owned subsidiary of The Kroger Co. (NYSE: KR). The regional grocery chain employs approximately 30,000 associates and operates stores in North Carolina, South Carolina, Virginia, Georgia, Maryland, Delaware, Florida and the District of Columbia.

Share article on social media or email:

HR professionals and business leaders must open and expand the dialogue about workplace benefits with executives and decision-makers. Our employees are counting on us.

NEW YORK (PRWEB)
March 26, 2020

Using the expertise of industry leaders to explore solutions to problems facing the ever-changing corporate landscape, Mediaplanet today announces the launch of its March edition of their campaign, “Employee Well-Being.” With topics covering millennial retention, financial wellness, pet health insurance, physical and mental health, workplace harassment, diet and nutrition, and caregiving, the campaign emphasizes that when companies invest in the well-being of their employees, it leads to a more profitable bottom line for the employer.

The cross-platform campaign advocates for an increased emphasis on overall employee health, engagement, and benefits. By partnering with the HR industry’s most prominent thought leaders, the included stories highlight the importance for employers to expand employee benefits and development programs, implement HR efficiencies, and improve well-being solutions. Its ultimate aim is to help managers and HR professionals cultivate a happier, healthier, and more developed workforce, all while boosting company engagement, which improves retention and allows for the professional growth of top talent.

Chief Executive Officer of the Society for Human Resource Management, Johnny C. Taylor, is featured in the foreword of the publication. Inside, Taylor discusses a healthy work-life balance, paid leave, recruiting and retention, benefits for the multi-generational workforces, financial wellness resources, student loan debt relief, remote working, and telemedicine. “When employees feel supported by good benefits, they can spend more time managing life outside of work with less stress—whether it be through more flexibility, financial wellness, or health care accessibility,” Taylor said.

“HR professionals and business leaders must open and expand the dialogue about workplace benefits with executives and decision-makers. Our employees are counting on us.”

The print component of “Employee Well-Being” is distributed in today’s edition of USA Today New York, Los Angeles, Chicago, San Francisco, Washington DC/Baltimore, and Boston. In addition, it will be distributed at several industry-focused conferences, including Recruitcon, SHRM Annual Conference, HR World Conferences, the HRD Summit, and more. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here.

This campaign was made possible with the support of the Society for Human Resource Management, Health Enhancement Research Organization, the American Institute of Stress, National Business Group on Health, Patagonia, Nationwide Insurance, California Chamber of Commerce, Bright Horizons, Personal Capital, Talkspace, Oh My Green, Dave’s Killer Bread, and WebMD.

About Mediaplanet

Mediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do.

Press Contact:

Katie McNerney

katherine.mcnerney@mediaplanet.com

(646)-619-0195

Share article on social media or email:

Medopad COVID-19 RPM

Now is the time for global collaboration to help ease the burden of COVID-19 on our healthcare systems, reduce disease spread through remote patient monitoring and maintain the continuity of care for at-risk populations.”

LONDON (PRWEB)
March 26, 2020

As healthcare systems are overwhelmed in the face of the COVID-19 pandemic, British healthtech company Medopad is offering immediate support by providing its Remote Patient Monitoring (RPM) software at cost to NHS Trusts across the UK and global healthcare providers. Medopad has worked with clinicians from Imperial College, Guys and St Thomas’s NHS Foundation Trust and Johns Hopkins to create a readily available, out-of-box version of its modular RPM platform configured for tracking COVID-19 that can be deployed in days. Through its RPM software, Medopad helps healthcare systems monitor ill and at-risk patients, enable care for chronically ill patients and provide insights to healthcare systems to help them prioritise resources and respond more effectively.

To further support healthcare systems, Medopad is also working with its global partners, including Johns Hopkins and Tencent, to clinically validate digital biomarkers to identify individual patient risk for COVID-19 and monitor respiratory symptoms and disease progression using only a smartphone.

Monitoring COVID-19 Patients and Protecting the Vulnerable

The WHO, NHS, and FDA have formally recommended that healthcare systems use telemedicine and RPM during the COVID-19 public health emergency to reduce the strain on healthcare systems and limit disease spread. Medopad’s clinically validated RPM solutions are secure, infrastructure-ready and scalable to address the demands on healthcare systems and providers, enabling more global understanding of the disease. Medopad’s RPM solution is CE registered and under FDA enforcement discretion and is ready to be deployed in the EU, US, China, Singapore, Hong Kong, Saudi Arabia and beyond for supporting patient care with chronic conditions and configurable for rare diseases.

Medopad’s app and clinician dashboard help track patient data and symptom progression to maintain ongoing patient care and support, flag patients with worsening symptoms and notify clinicians of a patient’s deteriorating health when they are out of the clinical setting. The patient’s mobile app allows them to opt-in to securely share personal health data, including vital signs such as temperature, respiration rate, and heart rate using their smartphone. Medopad has pioneered its RPM solution across fifteen NHS trusts in the UK in the past two years, working with Trusts like Chelsea and Westminster Foundation Trust on diseases like Heart Failure to to reduce the unpredictability of patients presenting at A&E by collecting data and information on heart failure patients when outside of hospital settings.

“As part of the NHSE Test Bed Programme we partnered with Medopad to empower our patients. Through the continuous monitoring of their health, we aim to reduce pressure on A&E and outpatients and avoid hospital admissions and reduce hospital bed days. During the COVID-19 crisis, Medopad’s solution can allow hospitals to continuously monitor and engage with their patients without the need to bring them into the healthcare system where there is an elevated risk of them contracting COVID-19,” commented Felix Vaal, Senior Project Manager for Digital Innovation, Chelsea and Westminster Trust.

Developing a COVID-19 Biomarker: Using a Smartphone to Monitor Symptoms and Disease Progression

Medopad is prioritising R&D efforts for novel technologies that could help reduce the spread and management of COVID-19. Medopad is collaborating with Johns Hopkins and key opinion leaders from Imperial College and other major academic partners to fast-track the development and validation of a digital biomarker to determine an individual risk profile for COVID-19.

“We have been working in collaboration with Medopad for over a year on a digital biomarker project. COVID-19 presents an opportunity for us to take this work further and develop a specific COVID-19 digital biomarker. The aim is to adjust the data points collected and focus specifically on cardio-respiratory diseases, diabetes and other conditions which compromise the immune system to identify those who are most at risk should they contract COVID-19,” added Alain Labrique, Associate Professor at Johns Hopkins Bloomberg School of Public Health.

Medopad is also developing a way to use a smartphone’s gyroscope-powered motion sensors to accurately measure an individual’s heart and respiratory rate without the need for additional hardware by placing a phone on the patient’s chest wall for 30-60 seconds. Developing and validating this digital biomarker, combined with other data points, will enable more efficient COVID-19 patient monitoring and clinical team support by remotely tracking vital signs that indicate the severity of COVID-19.

Dan Vahdat, founder and CEO of Medopad, commented, “This is an unprecedented global health crisis that requires a global response. To do our part, Medopad is providing our platform and development efforts to aid in the fight of the COVID-19 pandemic. We have already had initial success detecting digital biomarkers for rare and chronic diseases like Parkinson’s, Alzheimer’s and are now shifting most of our resources towards COVID-19 efforts. Now is the time for global collaboration to help ease the burden of COVID-19 on our healthcare systems, reduce disease spread through remote patient monitoring and maintain the continuity of care for at-risk populations.”

Medopad is conducting feasibility studies and clinical trials to validate its digital biomarkers for detecting and assessing diseases and health conditions such as Parkinson’s with partners including Tencent, J&J, Bayer and more. It is now working with partners including Johns Hopkins and Tencent to fast-track the development and validation of a specific digital biomarker for COVID-19 using only a smartphone.

“The joint Medopad and Tencent Medical AI lab have been working for the last 2 years on various digital biomarker projects. COVID-19 presents an opportunity for us to modify some of our R&D work to showcase the power of using smartphones and simple devices to capture data directly from patients and the population at large and generating novel insights from it. Together with our academic partners, we are working on a number of digital biomarkers which can be done with only a smartphone to help unlock valuable data to better understand and treat COVID-19. While moving at pace, we continue to work closely with regulators and design our technology to maximise data privacy,” and Dr. David Wei Fan, Executive Director of Tencent Medical AI Lab.

About Medopad

Medopad is a global health technology company that aims to use data and technology to give everyone the full picture of patients’ health to help people live longer, fuller lives. Medopad partners with the world’s largest healthcare systems, pharma companies, research institutes, insurers and technology companies like Apple and Tencent to create a connected health ecosystem that empowers patients, improves clinical outcomes and enables the future of healthcare. http://www.medopad.com

Share article on social media or email: